New hope for Hard-to-Treat cancers: targeted drug HRS-6093 enters human testing
NCT ID NCT07134998
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-stage study tests an experimental drug called HRS-6093 in people with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 153 participants will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
Conditions
Explore the condition pages connected to this study.